MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Quotient Limited Operating Income 2011-2026 | QTNT
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Quotient Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -82.7 M | -80.4 M | -79.2 M | -70 M | -74.1 M | -49.1 M | -29.7 M | -8.89 M | -4.49 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.49 M | -82.7 M | -53.2 M |
Quarterly Operating Income Quotient Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.6 M | -89.1 M | -63.5 M | - | -31.3 M | -77 M | -45.7 M | -22 M | -21.6 M | -21.7 M | -13.1 M | -19.7 M | -22.4 M | -22.4 M | -18.4 M | -18.4 M | -19 M | -19 M | -21.1 M | - | -17.1 M | -18.1 M | -16.9 M | - | -22.4 M | -56.3 M | -33.9 M | - | -12.8 M | -36.2 M | -23.5 M | - | -7.33 M | -20 M | -12.6 M | - | -2.8 M | -4.29 M | -1.49 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.49 M | -89.1 M | -26 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 17.01 | -0.09 % | $ 179 M |  China |
 |
Agilent Technologies
A
|
1.35 B | $ 117.69 | 0.14 % | $ 35.8 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 20.94 | 1.16 % | $ 1.12 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.64 | 3.14 % | $ 2.18 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.75 | 0.61 % | $ 687 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Medpace Holdings
MEDP
|
535 M | - | - | $ 12.3 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 181.73 | -1.97 % | $ 9.01 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.11 | -18.29 % | $ 381 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.89 | 0.34 % | $ 1.14 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.86 | -4.7 % | $ 400 M | USA |
 |
Natera
NTRA
|
-541 M | $ 215.09 | 4.02 % | $ 21.2 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.92 | 0.13 % | $ 451 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.23 | 2.95 % | $ 20 B |  Niderland |
 |
Personalis
PSNL
|
-68.3 M | $ 6.07 | 9.17 % | $ 360 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 92.25 | 3.05 % | $ 11.6 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.94 | 0.04 % | $ 2.69 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 124.13 | 2.32 % | $ 10.2 B |  Irlanda |
 |
Illumina
ILMN
|
-833 M | $ 142.58 | 2.52 % | $ 22.7 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.36 | 7.2 % | $ 224 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | - | - | $ 9.33 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 472.95 | 1.33 % | $ 178 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.21 | 1.14 % | $ 5.08 M | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.6 | 0.42 % | $ 61.9 M | Irlanda |
 |
Lantheus Holdings
LNTH
|
311 M | $ 86.15 | 0.38 % | $ 5.81 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 256.94 | -0.08 % | $ 21.4 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 59.53 | 4.99 % | $ 3.56 B | USA |
 |
Celcuity
CELC
|
-172 M | - | - | $ 6.52 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.18 | -0.97 % | $ 1.99 B | USA |
 |
Waters Corporation
WAT
|
271 M | $ 349.53 | 1.98 % | $ 20.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 189.13 | -0.9 % | $ 21 B | USA |